Eric D. is an Automotive Journalist at the Detroit Free Press. He covers Stellantis, formerly known as Fiat Chrysler, along with various transit and mobility topics, often focusing on the intersections of automotive developments and healthcare themes. Eric's work has been featured in numerous publications including MDPI, Nature Portfolio, and USA TODAY, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Eric D.'s coverage heavily focuses on the automotive industry, with particular attention to labor unions and political impact. This suggests that he may be most interested in pitches related to the automotive sector's economic and political dynamics, particularly those involving Stellantis or UAW.
Given Eric's reporting on government announcements and use of data, he might respond well to pitches offering analysis or commentary from experts with insights into regulatory changes affecting the automotive industry in the US. Additionally, considering his focus on labor unions, sources involved in union activities within major automakers could make for relevant pitching targets.
For topics like cancer research or agricultural studies mentioned in some article titles as an outlier, it would be essential to understand if these are regular features by Eric D., which can guide whether these areas are also potential pitching opportunities based on future articles published by him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Department of Microbiology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
The global distribution and climate resilience of marine heterotrophic prokaryotes
Abstract Background To characterize a cohort of ventilator-dependent infants and children with bronchopulmonary dysplasia-associated
Abstract Accurate assessment of therapy response in myelodysplastic neoplasm (MDS) has been challenging.
Background/Objectives: Mucin-1 (MUC1) is a transmembrane glycoprotein that is overexpressed and hypoglycosylated in premalignant and malignant epithelial cells compared to normal cells, creating a target antigen for humoral and cellular immunity. Healthy individuals with a history of advanced colonic adenomas and at high risk for colon cancer were enrolled in a clinical trial to evaluate the feasibility of using a MUC1 peptide vaccine to prevent colon cancer. Anti-MUC1 antibodies elicited by this vaccine were cloned using peripheral blood B cells and sera collected two weeks after a one-year booster. Twelve of these fully human monoclonal antibodies (mAb) were tested for binding to MUC1+ target cells, and three with the highest binding were further evaluated for various effector functions important for tumor rejection. Methods: Immune cells were incubated together with target cells expressing variations in the number, distance, and membrane anchoring properties of the MUC1 epitope in the presence of each mAb. Results: All three mAbs mediated antibody-dependent cytokine release (ADCR), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). Two also mediated antibody-dependent trogocytosis/trogoptosis (ADCT). None were capable of complement-dependent cytotoxicity (CDC). Conclusions: ADCP and ADCT functions were more efficient when antibodies bound epitopes proximal to and anchored to the membrane, providing insight for future therapeutic antibody validation strategies.
By: Lyman Briggs
Abstract In recent years, legislators in many states have proposed laws governing the use of psychiatric electroceutical interventions (PEIs), which
Produce Safety and Microbiology Research Unit, Western Regional Research Center, Agricultural Research Service, United States Department of Agriculture, Albany, CA 94710, USA
By: Ken Shubin, Simon Fraser
Abstract Emerging evidence from neurophysiological brain vital sign studies show repeatable sensitivity to cumulative subconcussive impairments over a season of contact sports.
By: Simon, Brian, Kevin L., Christopher D., Goguet, Ramirez, Edward, Emilie, Eric D., Wei, Smith, Danielle W.,, Maggie L., Christopher C., Carol D.
The ongoing emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants underscores the need for rapid, adaptable, high-throughput testing. However, assays for neutralizing antibodies, which are a good measure of viral protection, usually require cell culture and either infectious SARS-CoV-2 or pseudotyped viral particles. To circumvent the challenges of cell-based assays, SARS-CoV-2 surrogate virus neutralization tests (sVNTs) measure inhibition of the binding of the spike (S) protein receptor binding domain (RBD) to its receptor, human angiotensin-converting enzyme 2 (hACE2) by neutralizing antibodies. Here we tested a prototype automated microfluidic cartridge-based sVNT platform using SARS-CoV-2 wild-type (WT) and B.1.617.2 (Delta) variant RBDs. This sVNT showed a high correlation with cell-based neutralization assays for biospecimens collected post-COVID-19 vaccination and post-SARS-CoV-2 infection as well as for pre-pandemic SARS-CoV-2 negative sera. Thus, this assay, which takes less than 80 min, is a relatively simple, safe, and accurate alternative to traditional VNTs.
By: Lindsey A., Gordzevich, Denise, Melissa E., Hamilton, Kenneth, Speagle, Eric D., Jonathan M., Craig R., Megan M.
Expression of VIM-2 leads to physiological trade-offs for bacterial pathogens that can be exploited to treat infections caused by multidrug-resistant bacteria.
(833) 317-6278 
